Latest news with #BakheetAlKatheeri
Al Etihad
21-05-2025
- Business
- Al Etihad
Borouge, Mubadala Bio sign agreement to strengthen UAE's healthcare, life sciences sectors
21 May 2025 19:14 ABU DHABI (WAM)Borouge, a leading petrochemicals company, that provides innovative and differentiated polyolefins solutions, has signed a strategic cooperation agreement with Mubadala Bio, a life sciences company dedicated to pursuing better health outcomes for the UAE and partnership will explore the supply of polyolefin materials to enable local manufacturing of medical products, reinforcing local manufacturing capabilities while contributing to the future of the UAE's healthcare and life sciences signing ceremony was witnessed by Dr. Sultan bin Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Managing Director and Group CEO of ADNOC, Dr. Bakheet Al Katheeri, Chief Executive Officer, UAE Investments Platform, Mubadala, and Ismail Ali Abdulla, Executive Director of UAE Clusters, Sultan Al Suwaidi, CEO of Borouge, and Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, signed the agreement during Make it in the Emirates, a flagship UAE event that unites industry leaders to drive innovation and industrial Al Suwaidi said, "We are delighted to partner with Mubadala Bio to explore the development of essential medical solutions made at our Ruwais facility in the UAE. Aligned with the ambitions of Make it in the Emirates, this collaboration goes beyond the supply of materials, it is about combining the UAE's scientific product innovation with regional insight to bring smarter, safer products for patients and clinicians across the Middle East and beyond."Ismail Abdulla added, "This collaboration agreement with Borouge reflects Mubadala Bio's commitment to enabling a world-class, sustainable life sciences sector anchored in advanced local manufacturing. By collaborating with local partners, we aim to grow the manufacturing of UAE-made products. We are strengthening the life sciences sector, supporting the UAE's vision, and enhancing the delivery of essential health products for communities locally and abroad."Powered by Borealis' Borstar technology, Bormed RG868MO, produced by Borouge in the UAE, marks a key milestone as the initial product offering in Borouge's wider healthcare RG868MO provides transparency and mechanical strength, and meets industry sterilisation standards, making it ideal for pharmaceutical packaging and medical devices like three-part syringes, inhalers, pharmaceutical caps and product is already in production at Borouge's manufacturing plant in Al Ruwais Industrial City, Abu Dhabi, representing the first time it has been made for healthcare applications in the UAE. Borouge is set to launch its second healthcare product by the end of the year, building on the momentum of its current Middle East rollout. Aligned with Borouge's commitment to sustainability and innovation, this healthcare solution enables customers to reduce production cycle times through faster processing, and can provide an estimated carbon footprint reduction of 5 - 10%.
Arabian Post
20-05-2025
- Business
- Arabian Post
Mubadala Bio Emerges as Pillar of UAE's Healthcare Vision
Mubadala Investment Company has unveiled Mubadala Bio, a new life sciences entity designed to bolster the United Arab Emirates' pharmaceutical manufacturing capabilities and enhance healthcare resilience. The initiative aligns with the country's Centennial 2071 vision, aiming to position Abu Dhabi as a regional hub for biopharmaceutical innovation. Mubadala Bio's infrastructure encompasses ten facilities across Asia, Africa, and Europe, with six situated within the UAE. Collectively, these sites span 110,000 square metres and possess an annual production capacity exceeding 2.5 billion tablets and capsules, along with 120 million intravenous and injectable units. The company's extensive portfolio includes over 10,000 medical products, serving more than 100 countries worldwide. The company's focus extends across the entire continuum of care, from prevention and diagnostics to treatment and supportive therapies. This comprehensive approach aims to address pressing global health challenges and improve patient outcomes. Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform, stated that the launch of Mubadala Bio represents a transformative step toward strengthening national drug security and fostering innovation in life sciences. He emphasized that this positions Mubadala at the forefront of the industry, enabling long-term economic growth and the development of a resilient life sciences ecosystem. Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala, highlighted the company's commitment to supporting the UAE's ambition to become a global leader in the life sciences industry. By focusing on local manufacturing and enhancing distribution and logistics capabilities, Mubadala Bio aims to build a self-sustaining sector prepared for future challenges. Mubadala Bio plans to establish strategic partnerships with global life sciences firms and academic institutions to accelerate biopharmaceutical innovation and nurture world-class talent within the UAE. These collaborations are intended to drive advancements in healthcare and support the country's transition to a knowledge-based economy. See also UAE Airlines Resume Flights to Pakistan After Airspace Reopening The company's launch will be formally introduced at the upcoming Make it in the Emirates 2025 event, showcasing the UAE's success in building a competitive life sciences industry. This event serves as a national industrial showcase, reinforcing the country's position as a hub for innovation and local manufacturing. Mubadala Bio is designated as one of Mubadala's 'National Champions,' entities established to support strategic sectors aligned with the UAE's long-term development goals. Through its initiatives, the company aims to accelerate the UAE's economic diversification, particularly in healthcare and biotechnology.
Gulf Business
20-05-2025
- Business
- Gulf Business
Abu Dhabi: Mubadala launches new life sciences company
Image: Mubadala Mubadala Investment Company has announced launched Mubadala Bio, a life sciences company aimed at strengthening the UAE's pharmaceutical sector, improving health outcomes, and advancing economic diversification. The company will focus on national drug security, increased access to essential therapeutics and medical devices, and the development of a knowledge-based economy. The announcement was made ahead of Mubadala Bio's participation in Make it in the Emirates 2025. Mubadala Bio operations Mubadala Bio's operations include a network of 10 facilities across Asia, Africa, and Europe — six of which are located in the UAE — serving more than 100 countries. Collectively, the facilities span 110,000 square meters and have an annual production capacity exceeding 2.5 billion tablets and capsules and 120 million IVs and injectables. The portfolio covers more than 10,000 products. The company's therapeutic focus spans the full continuum of care, from prevention and diagnostics to treatment and complementary medicine, and aims to address global health challenges. Mubadala Bio also intends to build long-term partnerships with global industry leaders and academic institutions to boost biopharma innovation and local manufacturing. Strategic move for national resilience 'By launching Mubadala Bio, we are taking a transformative step towards strengthening national drug security and fostering innovation in life sciences,' said Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform. 'This positions Mubadala at the forefront of the industry and enables us to drive long-term economic growth and a resilient ecosystem.' Building for the future Ismail Ali Abdulla, ED of UAE Clusters at Read:
Mid East Info
19-05-2025
- Business
- Mid East Info
Mubadala Launches its Latest National Champion – 'Mubadala Bio' to Transform Life Sciences in the UAE and Beyond
With a focus on enabling local manufacturing and distribution of therapies, Mubadala Bio is reinforcing national drug security and positioning Abu Dhabi as a regional hub for life sciences Abu Dhabi, May 2025 – Mubadala Investment Company PJSC (Mubadala), an Abu Dhabi sovereign investor, today announced the launch of Mubadala Bio, a life sciences company committed to strengthening the life sciences sector in the UAE and advancing better health outcomes for the UAE and the world. The launch of this National Champion represents a strategic step that reflects Mubadala's commitment to healthcare resilience, strengthening drug security, expanding access to essential, high-quality therapeutics and medical devices, and accelerating the UAE's economic diversification and building a knowledge-based economy. Mubadala Bio's integrated portfolio includes 10 facilities spans across Asia, Africa and Europe (with 6 located within the Emirates), serving over 100 countries. Across these sites, the cumulative manufacturing capacity of its facilities exceeds 2.5 billion tablets and capsules, 120 million IVs and injectables annually, and spans 110,000 square meters – enabling the production and global distribution of more than 10,000 products. Mubadala Bio's portfolio focuses on key therapy areas that address some of the world's most pressing health needs, supporting the full continuum of care, from prevention and diagnosis to treatment, ongoing support, and complementary medicine. By forging long-term strategic partnerships with global industry leaders and top-tier academic institutions, Mubadala Bio is accelerating biopharma innovation and local manufacturing, cultivating world-class talent and driving accelerated advancements. This holistic strategy spans the full continuum of care by providing integrated disease solutions across prevention, diagnostics, treatment, supportive treatment, and complementary medicine. Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala's UAE Investments Platform, said: 'By launching Mubadala Bio, we are taking a transformative step towards strengthening national drug security and fostering innovation in life sciences. This positions Mubadala at the forefront of the industry, enabling us to drive long-term economic growth, build a resilient life sciences ecosystem, and elevate Abu Dhabi's role in delivering impactful health solutions on a global scale. Through our National Champions, we continue our efforts to accelerate the UAE's economic diversification by investing in priority sectors and support building a knowledge-based economy. Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform, added: 'With the launch of Mubadala Bio, we are proud to take a significant step forward in supporting the UAE's ambition to be a global leader in the life sciences industry. By focusing on local manufacturing and enhancing our distribution and logistics capabilities, we are building a more resilient and self-sustaining life sciences sector, one that responds to today's needs while preparing for tomorrow's challenges.' Focusing on integrated biopharma and pharma logistics, Mubadala Bio aims to support the UAE's Centennial 2071 vision. As part of its launch, it will mark its first physical presence at Make it in the Emirates 2025, showcasing the UAE's success in building a competitive life sciences industry and reinforcing its position as a hub for innovation and local manufacturing. About Mubadala: Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi. Mubadala's US$330 billion (AED 1,212 billion) portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates. About Mubadala Bio: Mubadala Bio, a wholly owned subsidiary of Mubadala Investment Company, launched in 2025, is a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond. With a growing presence across the UAE, Asia, Africa, and Europe, Mubadala Bio is advancing drug security, improving access to essential therapeutics, and accelerating the development of a sustainable life sciences sector, aligned with the UAE's vision for a knowledge-based economy. Operating across two core verticals — Integrated Biopharma and Pharma Logistics — Mubadala Bio focuses on local manufacturing and distribution to ensure the availability of the most critical and in-demand medical therapies. Mubadala Bio focuses on some of the world's most pressing therapy areas, supporting the full continuum of care. Mubadala Bio is committed to affordability, global partnerships, and investing in national talent to help shape the future of healthcare locally and worldwide.
Web Release
19-05-2025
- Business
- Web Release
Mubadala Launches its Latest National Champion – 'Mubadala Bio' to Transform Life Sciences in the UAE and Beyond
Mubadala Investment Company PJSC (Mubadala), an Abu Dhabi sovereign investor, today announced the launch of Mubadala Bio, a life sciences company committed to strengthening the life sciences sector in the UAE and advancing better health outcomes for the UAE and the world. The launch of this National Champion represents a strategic step that reflects Mubadala's commitment to healthcare resilience, strengthening drug security, expanding access to essential, high-quality therapeutics and medical devices, and accelerating the UAE's economic diversification and building a knowledge-based economy. Mubadala Bio's integrated portfolio includes 10 facilities spans across Asia, Africa and Europe (with 6 located within the Emirates), serving over 100 countries. Across these sites, the cumulative manufacturing capacity of its facilities exceeds 2.5 billion tablets and capsules, 120 million IVs and injectables annually, and spans 110,000 square meters – enabling the production and global distribution of more than 10,000 products. Mubadala Bio's portfolio focuses on key therapy areas that address some of the world's most pressing health needs, supporting the full continuum of care, from prevention and diagnosis to treatment, ongoing support, and complementary medicine. By forging long-term strategic partnerships with global industry leaders and top-tier academic institutions, Mubadala Bio is accelerating biopharma innovation and local manufacturing, cultivating world-class talent and driving accelerated advancements. This holistic strategy spans the full continuum of care by providing integrated disease solutions across prevention, diagnostics, treatment, supportive treatment, and complementary medicine. Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala's UAE Investments Platform, said: 'By launching Mubadala Bio, we are taking a transformative step towards strengthening national drug security and fostering innovation in life sciences. This positions Mubadala at the forefront of the industry, enabling us to drive long-term economic growth, build a resilient life sciences ecosystem, and elevate Abu Dhabi's role in delivering impactful health solutions on a global scale. Through our National Champions, we continue our efforts to accelerate the UAE's economic diversification by investing in priority sectors and support building a knowledge-based economy. Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform, added: 'With the launch of Mubadala Bio, we are proud to take a significant step forward in supporting the UAE's ambition to be a global leader in the life sciences industry. By focusing on local manufacturing and enhancing our distribution and logistics capabilities, we are building a more resilient and self-sustaining life sciences sector, one that responds to today's needs while preparing for tomorrow's challenges.' Focusing on integrated biopharma and pharma logistics, Mubadala Bio aims to support the UAE's Centennial 2071 vision. As part of its launch, it will mark its first physical presence at Make it in the Emirates 2025, showcasing the UAE's success in building a competitive life sciences industry and reinforcing its position as a hub for innovation and local manufacturing. For more information about Mubadala Bio and its initiatives, please visit
